Newfoundland Diagnostics
This article, Newfoundland Diagnostics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
This article, Newfoundland Diagnostics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
This article, Newfoundland Diagnostics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
This article, Newfoundland Diagnostics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Comment: Not quite enough independent, significant coverage. WikiOriginal-9 (talk) 18:38, 6 November 2023 (UTC)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/d/df/Newfoundland_Diagnostics_Logo.jpg/220px-Newfoundland_Diagnostics_Logo.jpg)
Newfoundland Diagnostics is a multinational health-testing company headquartered in London, United Kingdom. The company specializes in the development and distribution of diagnostic health tests, both for self-use and professional applications,[1] offering such products available in major retailers for the first time in the United Kingdom.[2]
History
Newfoundland Diagnostics was founded in 2020, focusing initially on the distribution of Covid-19 rapid antigen tests. It served as a distributor for Acon Biotech's Flowflex test during the Covid-19 pandemic, becoming a leader player in this field, in the United Kingdom,[3] with revenue of over £100m in its first two years of trading.[4]
The company was instrumental in offering diagnostic kits for various medical conditions, such as Thyroid function, Bowel health, Menopause, Kidney health, and HIV, in a major retailer, notably for the first time in the United Kingdom,[5] and pharmacies across the country.[6][7]
HIV Rapid Testing
In June 2023, Newfoundland Diagnostics entered into an exclusive supply agreement with Atomo Diagnostics (ASX: AT1), for the distribution of rapid self-test HIV kits at retailers in the United Kingdom and Europe.[8][9] This gained notoriety as the world's first commercially available, at-home HIV test, which was sold in major retailers, such as Tesco.[10][11]
Recent Developments
In October 2023, the company responded to the anticipated increase in Strep A cases following the 2022–2023 United Kingdom group A streptococcus outbreak by launching Strep A tests in Tesco stores and pharmacies across the United Kingdom.[12] The company aims to provide enough tests to cover 90% of the United Kingdom's at-home testing market.[13][14][15]
Market Presence and Competitive Landscape
As of 2023, Newfoundland Diagnostics holds one of the largest market shares in the United Kingdom for at-home diagnostic tests.[1] The company's networks extend into public health sectors, pharmaceutical industries, and retail channels across the United Kingdom and Europe. It has also begun to make inroads into the European self-test diagnostic market.[16]
References
- ^ a b "Service launches to allow quick diagnostic test turnaround". Med-Tech Innovation. 2023-08-16. Retrieved 2023-11-01.
- ^ Editor, Holly Williams, PA Business; Maule, Will (2023-02-27). "Tesco to stock at-home self-diagnosis health tests nationwide". Wales Online. Retrieved 2023-11-01.
{{cite web}}
:|last1=
has generic name (help)CS1 maint: multiple names: authors list (link) - ^ "Sigma teams up with Newfoundland Diagnostics". www.pharmacymagazine.co.uk. Retrieved 2023-11-01.
- ^ "Companies House Financial Accounts".
- ^ "Tesco launches at home tests to shoppers across the UK in first-of-its-kind deal". Lancashire Telegraph. 2023-02-27. Retrieved 2023-11-01.
- ^ "At-home health tests launch in Tesco stores nationwide". The Independent. 2023-02-27. Retrieved 2023-11-01.
- ^ "Sigma teams up with Newfoundland Diagnostics". www.pharmacynetworknews.com. Retrieved 2023-11-01.
- ^ "Atomo and Newfoundland sign agreement for HIV testing in Europe". biotechdispatch.com.au. Retrieved 2023-11-01.
- ^ Seymour, Julia (2023-02-28). "Atomo Diagnostics (ASX:AT1) secures $900k order for HIV self-tests". The Market Herald. Retrieved 2023-11-01.
- ^ "Tesco launches at home tests to shoppers across the UK in first-of-its-kind deal". The Argus. 2023-02-27. Retrieved 2023-11-01.
- ^ 161385360554578 (2023-11-30). "At-home HIV tests launched in supermarkets for first time". The Sun. Retrieved 2023-11-30.
{{cite web}}
:|last=
has numeric name (help) - ^ "Strep A tests launching in Tesco and pharmacies to help combat winter shortages". www.expressandstar.com. 2023-10-30. Retrieved 2023-11-01.
- ^ Williams, Holly (2023-10-30). "Strep A tests launching in Tesco and pharmacies to help combat winter shortages". Evening Standard. Retrieved 2023-11-01.
- ^ Staff, A. O. L. (2023-10-30). "Strep A tests launching in Tesco and pharmacies to help combat winter shortages". www.aol.co.uk. Retrieved 2023-11-01.
- ^ "First at-home HIV tests launched in Tesco as sufferers say stigma continues". The Independent. 2023-11-30. Retrieved 2023-11-30.
- ^ MarketScreener (2023-02-27). "Atomo Diagnostics Limited Announces Significant Purchase Order for HIV Self-Tests for Europe -February 27, 2023 at 04:58 pm EST | MarketScreener". www.marketscreener.com. Retrieved 2023-11-01.